logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Interim Analysis Of Phase 3 MonarchE Study

Eli Lilly and Company (LLY) said the results from a pre-planned interim analysis of the Phase 3 monarchE study of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free survival, significantly decreasing the risk of breast cancer recurrence or death compared to standard adjuvant endocrine therapy alone. The safety profile was consistent with that observed in other Verzenio studies.

Lilly plans to present the data from the interim analysis at a medical meeting later this year. The monarchE trial will continue through the completion date, anticipated for June 2027.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
Follow RTT